[EN] QUINOLINE COMPOUNDS AS CETP INHIBITORS<br/>[FR] COMPOSES DE QUINOLINE EN TANT QU'INHIBITEURS DE CETP
申请人:PFIZER PROD INC
公开号:WO2006033004A1
公开(公告)日:2006-03-30
Quinoline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDLcholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
A Cu-catalyzedregio- and enantioselective hydroboration of 1,2-dihydroquinolines with high yields and excellent enantioselectivities (up to 98% ee) was presented. This method could be applied in the asymmetric synthesis of the important intermediates used in the enantioselectivesynthesis of the potential agent Sumanirole for the treatment of Parkinson’s disease and of the potentially interesting